Browse the evidence

Several emerging oral agents have demonstrated promising efficacy, achieving weight loss of ≥10% in clinical trials.

Practitioners may consider these oral agents as effective options for weight management.

Incretin-based therapy reduced all-cause mortality by 18%.

Incretin-based therapies may improve survival rates in overweight or obese individuals.

The total daily dose (TDD) of insulin decreased from 183 ± 98 units to 143 ± 99 units over 6 months (P < 0.001).

Clinicians may consider semaglutide as a viable option to reduce insulin requirements in T2DM patients.

Obesity leads to inflammation and altered hormone production that can promote cancer development.

Understanding the hormonal and inflammatory changes in obesity can help in developing targeted interventions for cancer prevention.

Semaglutide was associated with a reduction in heavy drinking days by -41.1 percentage points from baseline compared to placebo, which had a reduction of -26.4 percentage points.

Semaglutide may be a viable treatment option for reducing heavy drinking in patients with alcohol use disorder and obesity.

Semaglutide improved heart failure symptoms and physical limitations in participants with obesity-related HFpEF.

Practitioners can consider semaglutide as an effective treatment for improving symptoms in patients with obesity-related HFpEF.

Semaglutide treatment shows significant interactions based on sex at both 1.7 mg and 2.4 mg doses compared to placebo.

Clinicians should consider sex as a factor when prescribing semaglutide for weight loss.

Semaglutide 2.4 mg shows significant treatment interactions based on the presence of type 2 diabetes and dyslipidemia at baseline compared to placebo.

Healthcare providers should assess comorbidities when evaluating the potential effectiveness of semaglutide.

HEC-C046, with high GCG receptor selectivity, shows significant weight loss and improvement in MASLD parameters but raises safety concerns.

Practitioners should consider the balance between efficacy and safety when using dual receptor agonists.

HEC-C052, with the lowest GCG agonism, is less effective for weight loss compared to semaglutide.

Semaglutide may be preferred over HEC-C052 for weight loss in certain populations.

Randomized trials with liraglutide and semaglutide have shown reductions in major adverse cardiovascular events.

These medications may be beneficial for patients at high risk of cardiovascular events.

Tirzepatide was recently approved for the management of obesity.

Tirzepatide can be considered as a treatment option for obesity management.

Tirzepatide manages blood sugar levels and enhances weight loss more than GLP-1 receptor agonists.

Tirzepatide may be more effective than GLP-1 receptor agonists for patients needing blood sugar and weight management.

Continuing GLP-1 or GIP agonists before upper endoscopy increases the risk of clinically significant residual gastric volume (RGV).

Practitioners should consider holding GLP-1 or GIP agonists prior to upper endoscopy to reduce the risk of RGV.

Holding one dose of GLP-1 or GIP agonists significantly reduces the risk of clinically significant RGV.

Holding the medication prior to the procedure is advisable to minimize RGV risk.

Clear liquids the day prior to the procedure may mitigate the risk of clinically significant RGV regardless of GLP-1/GIP use.

Encouraging clear liquids before procedures may help reduce RGV risk.

Tirzepatide is available for the treatment of hyperglycemia in patients with type 2 diabetes.

Practitioners can consider tirzepatide as a treatment option for managing hyperglycemia in type 2 diabetes patients.

Tirzepatide is a novel treatment option for Type 2 diabetes mellitus (T2DM) that may benefit individuals with cardiovascular disease or heart failure.

Tirzepatide may be considered for T2DM patients with cardiovascular concerns.

Key gut hormones such as GLP-1, OXM, and PYY play a role in ameliorating Type 2 diabetes mellitus.

Therapies targeting GLP-1, OXM, and PYY may be beneficial for managing DM2.

Endocrine adaptations occur in athletes as a result of training.

Understanding hormonal changes can help tailor training programs for athletes.

Semaglutide improved glycemic control, with HbA1c decreasing by 0.4 ± 0.6%.

Semaglutide may be a beneficial treatment for improving glycemic control in patients with type 1 diabetes.

1 kg/m² lower BMI via the GIP/GIPR score is associated with 29% lower risk of major adverse cardiovascular events (MACE).

Targeting GIP receptor pathways may significantly reduce cardiovascular event risk.

1 kg/m² lower BMI via the GIP/GIPR score is associated with 43% lower risk of heart failure.

Targeting GIP receptor pathways may significantly reduce heart failure risk.

Menopause is associated with weight gain and a predisposition to obesity in women.

Practitioners should be aware of the increased risk of weight gain in menopausal women.